Dulaglutide Dosing Schedule: Titration, Timing, and Missed Doses

Dulaglutide at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Eli Lilly
• FDA approved: 2014
• Route: subcutaneous injection (single-use pen)
• Typical frequency: once weekly
• Half-life: approximately 5 days
• Cash price (US): $900-$1,000/month without insurance
• Receptor target: GLP-1 receptor

The wrong Dulaglutide dose — too high, too low, or escalated too quickly — is the most common reason people stop the drug. Dulaglutide starts at 0.

Standard Dosing Schedule for Dulaglutide

Dulaglutide starts at 0.75 mg weekly and titrates up to 1.5, 3.0, or 4.5 mg based on tolerance and glycemic response. Most patients reach the 1.5 mg dose; weight-loss benefit is greater at higher doses.

The typical schedule for Dulaglutide is once weekly via subcutaneous injection (single-use pen). Half-life of approximately 5 days explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For incretin therapies, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms (nausea, vomiting, diarrhea).

A typical titration plan for Dulaglutide holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Dulaglutide is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 5 days) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Dulaglutide side effects and the cost angle of dose escalation in Dulaglutide cost.

What the Trials Used

Published trial data for Dulaglutide comes primarily from: REWIND trial (Gerstein 2019, Lancet) — 12% relative reduction in major cardiovascular events over 5.4 years.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Dulaglutide: the personal or family history of medullary thyroid carcinoma, MEN 2 syndrome apply.

Bottom Line

Most Dulaglutide dose questions resolve in a 5-minute conversation with a clinician. Don't carry them around — get them answered.

Frequently Asked Questions

Related Reading

• Dulaglutide Explained: How It Works and Who It's For
• Dulaglutide Side Effects Decoded: What's Normal vs. What Isn't
• Does Dulaglutide Really Work? An Evidence-Based Results Review
• The Real Dulaglutide Price Tag in 2026 — With and Without Insurance
• Liraglutide Explained: How It Works and Who It's For
• Liraglutide Side Effects: The Complete List and How to Handle Them

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.

This page is informational only and is not medical advice. Always follow your prescribing clinician's dosing instructions.